STRATA Skin Sciences, Inc. (SSKN)
| Market Cap | 765.47K |
| Revenue (ttm) | 30.70M |
| Net Income (ttm) | -6.26M |
| Shares Out | 5.89M |
| EPS (ttm) | -1.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,567 |
| Average Volume | 13,604 |
| Open | 0.122 |
| Previous Close | 0.122 |
| Day's Range | 0.122 - 0.134 |
| 52-Week Range | 0.110 - 3.860 |
| Beta | 0.34 |
| RSI | 36.91 |
| Earnings Date | May 14, 2026 |
About STRATA Skin Sciences
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy sy... [Read more]
Financial Performance
In 2025, STRATA Skin Sciences's revenue was $30.70 million, a decrease of -8.54% compared to the previous year's $33.56 million. Losses were -$6.26 million, -37.92% less than in 2024.
Financial StatementsNews
STRATA Skin Sciences Confirms Nasdaq Delisting
HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and market...
Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser
HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic ...
STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis
Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions Growing body of clini...
Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences
LAGUNA HILLS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Laseroptek America Corp. (“Laseroptek America” or “LOA”) today announced that it has filed counterclaims and third-party claims against Strata S...
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin A...
STRATA Skin Sciences Earnings Call Transcript: Q3 2025
Q3 2025 saw strong U.S. recurring revenue and record device billings, offset by a 20% drop in total revenue due to international headwinds. Expanded CPT codes and litigation wins are set to drive future growth, with TheraClearX expanding in Mexico and the U.S.
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion Higher reimbursement, regulatory ...
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update
HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and mark...
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTR...
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences' XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis
HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated ...
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marke...
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences' Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach
Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expand...
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering
HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marke...
STRATA Skin Sciences' Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements
Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention Consulting program optimizes partner...
STRATA Skin Sciences Earnings Call Transcript: Q2 2025
Q2 2025 revenue declined 9% year-over-year to $7.7M, mainly due to international headwinds, but expanded CPT codes and new clinical evidence position the business for significant growth in 2026. Litigation against LaserOptec progressed, and CMS decisions on reimbursement are pending.
STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients
Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (GL...
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and market...
STRATA Skin Sciences Earnings Call Transcript: Q1 2025
Q1 2025 saw continued growth in recurring revenue per device, margin expansion, and improved cash flow, driven by strategic initiatives like Elevate 360 and TheraClearX deployment. International revenue rose 8%, but future results may be impacted by tariffs.
STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketi...
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketi...
STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update
HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketi...
STRATA Skin Sciences Earnings Call Transcript: Q4 2024
Q4 2024 saw 10% revenue growth, record international sales, and improved gross margin to 60%. Device utilization and average revenue per device rose, while operating loss narrowed significantly. Strong cash position and strategic execution support a positive 2025 outlook.
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marke...
STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marke...
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marke...